Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: BJU Int. 2015 Dec 13;118(2):264–271. doi: 10.1111/bju.13374

Table 2. Adverse Events (N=88).

Adverse Event All Grades Grade I Grade 2 Grade 3
Fatigue 51 (58%) 31 (35%) 18 (21%) 2 (2%)
Diarrhea 34 (39%) 24 (27%) 9 (10%) 1 (1%)
HTN exacerbation 38 (43%) 24 (27%) 12 (14%) 2 (2%)
Anorexia/ Weight loss 24 (27%) 15 (17%) 8 (9%) 1 (1%)
Nausea/Vomiting 21 (24%) 13 (15%) 8 (9%) -
Increased LFTs 17 (19%) 2 (2%) 3 (3%) 12 (14%)
Hair and skin changes 12 (14%) 5 (6%) 7 (8%) -
Myalgias/Arthragias 9 (10%) 7 (8%) 2 (2%) -
Abdominal pain 7 (8%) 4 (5%) 2 (2%) 1 (1%)
New-onset HTN 5 (6%) 1 (1%) 4 (5%) -
Hypothyroidism 5 (6%) - 5 (6%) -

There were no Grade 4 adverse events.

HTN, hypertension; LFTs, liver function tests